Skip to main content
SpringerLink
Log in

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective

During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-β (IFNβ) and glatiramer acetate. This study aimed to perform a cost-analysis of the treatment of patients with RRMS in Italy after the introduction of these new agents.

Study design

This was a retrospective observational study with systematic patient inclusion.

Methods and results

Data gathered from 630 patients with confirmed RRMS over a 2-year period were evaluated. Overall, the direct cost over 2 years reached €11 073 100 thousand, corresponding to a per-patient cost of €17 576 (year of costing, 2001). The cost of disease-modifying agents represented approximately 77% of the total expenditure. IFNβ accounted for 94% of the expense of disease-modifying agents, corresponding to a 2-year cost per patient of €20 223. Although glatiramer acetate and immunoglobulins were also associated with a high level of expense, these were prescribed in only 3.8% and 1.1% of patients, respectively. Using regression analyses, IFNβ therapy, disability, number of days spent in hospital per year and the frequency of magnetic resonance imaging procedures were the main predictors of total costs.

Conclusion

Based on the results of this study, IFNβ treatment considerably modified the management of RRMS and was associated with a rise in cost of treatment per patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000; 343: 939–52

    Article  Google Scholar 

  2. Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997; 337: 1604–11

    Article  PubMed  CAS  Google Scholar 

  3. Hauser SL, Goodkin DE. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. Singapore: McGraw-Hill, 1998: 2409–19

    Google Scholar 

  4. Rosati G, Aiello I, Pirastru MI, et al. Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepi-demiology 1996; 15: 10–9

    Article  CAS  Google Scholar 

  5. Casetta I, Granieri E, Marchi D, et al. An epidemiological study of multiple sclerosis in central Sardinia, Italy. Acta Neurol Scand 1998; 98: 391–4

    Article  PubMed  CAS  Google Scholar 

  6. Granieri E, Malagu S, Casetta I, et al. Multiple sclerosis in Italy: a reappraisal of incidence and prevalence in Ferrara. Arch Neurol 1996; 53: 793–8

    Article  PubMed  CAS  Google Scholar 

  7. Istat — National Institute of Statistics. Available from URL: http://demo.istat.it/pop1/index.html [Accessed 2004 Mar]

  8. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249: 152–63

    Article  PubMed  Google Scholar 

  9. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61

    Article  Google Scholar 

  10. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–85

    Article  Google Scholar 

  11. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–504

    Article  Google Scholar 

  12. PRISMS-4 Study Group. Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56: 1628–36

    Article  Google Scholar 

  13. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–76

    Article  PubMed  CAS  Google Scholar 

  14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–7

    Article  PubMed  CAS  Google Scholar 

  15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–52

    Article  PubMed  CAS  Google Scholar 

  16. Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmaco-economics 1998; 13: 607–22

    Article  CAS  Google Scholar 

  17. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197–200

    Article  PubMed  CAS  Google Scholar 

  18. Zhou XH, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997; 127: 752–6

    PubMed  CAS  Google Scholar 

  19. Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 1998; 13: 597–606

    Article  PubMed  CAS  Google Scholar 

  20. Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil 1993; 74: 26–31

    PubMed  CAS  Google Scholar 

  21. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4: 419–25

    PubMed  CAS  Google Scholar 

  22. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002; 58: 37–43

    Article  PubMed  CAS  Google Scholar 

  23. Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95: 268–74

    Article  PubMed  CAS  Google Scholar 

  24. Grudzinski AN, Hakim Z, Cox ER, et al. The economics of multiple sclerosis: distribution of costs and relationship to disease severity. Pharmacoeconomics 1999; 15: 229–40

    Article  PubMed  CAS  Google Scholar 

  25. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998; 2: iii–54

    PubMed  CAS  Google Scholar 

  26. Brown MG, Murray TJ, Sketris IS, et al. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care 2000; 16: 751–67

    Article  PubMed  CAS  Google Scholar 

  27. Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon-β may be cost effective. Pharmacoeconomics 2000; 18(1): 45–53

    Article  PubMed  CAS  Google Scholar 

  28. Lepen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Invest 2003; 23(9): 571–81

    Article  CAS  Google Scholar 

  29. Forbes RB, Lees A, Waugh N, et al. Population-based cost utility study of interferon beta 1b in secondary progressive multiple sclerosis. BMJ 1999; 319: 1529–33

    Article  PubMed  CAS  Google Scholar 

  30. Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998; 121: 3–24

    Article  PubMed  Google Scholar 

  31. Paolillo A, Bastianello S, Frontoni M, et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta 1a. J Neurol 1999; 246: 443–8

    Article  PubMed  CAS  Google Scholar 

  32. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455–9

    Article  PubMed  CAS  Google Scholar 

  33. Trojano M, Granieri E, Rosati G, et al. The multiple sclerosis database network. Mult Scler 2003; 9( Suppl. 1): P424

    Google Scholar 

Download references

Acknowledgements

This study was supported by an unrestricted grant from Industria Farmaceutica Serono SpA. All opinions presented in this paper were expressed by the authors with full autonomy. The authors have provided no information on conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Human Physiology and Pharmacology, University of Rome “La Sapienza”, Rome, Italy

    Pierluigi Russo, Francesco Macchia & Luciano Caprino

  2. Clicon S.r.l., Health, Economics and Outcome Research, Ravenna, Italy

    Alessandro Capone & Luca Degli Esposti

  3. Department of Neurological Sciences, University of Rome “La Sapienza”, Rome, Italy

    Andrea Paolillo

  4. Neurologic Clinic I, University of Padua, Padua, Italy

    Federica Ranzato

  5. Ospedale Civile di Foggia, Foggia, Italy

    Gianfranco Costantino

Authors
  1. Pierluigi Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Capone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Paolillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Macchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Federica Ranzato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianfranco Costantino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luca Degli Esposti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luciano Caprino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierluigi Russo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Russo, P., Capone, A., Paolillo, A. et al. Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents. Clin. Drug Investig. 24, 409–420 (2004). https://doi.org/10.2165/00044011-200424070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200424070-00004

Keywords

Search

Navigation